Clinical Trial Update: Use of Activated Recombinant FVII in Spinal Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating activated recombinant factor VII for controlling bleeding in spinal surgery has been completed. The sponsor studied rFVIIa (NovoSeven) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Spinal Fusion | Phase 2 | Status: COMPLETED